Cytek Biosciences, Inc. - CTKB
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Nov 17, 2025 | SCHEDULE 13G | Topline Capital Management, LLC | 5.3% | 6,780,847 | View |
| Nov 17, 2025 | SCHEDULE 13G | Collin McBirney | 5.3% | 6,780,847 | View |
| Nov 17, 2025 | SCHEDULE 13G | Topline Capital Partners, LP | 5.3% | 6,780,847 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | Brown Capital Management, LLC | 3.9% | 4,958,016 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.